OSE Immunotherapeutics' Tedopi® Lung Cancer Trial Results to Debut at ESMO 2026 — OSE Immunotherapeutics SA

Event summary

OSE Immunotherapeutics will present topline results from the Combi-TED Phase 2 trial of Tedopi® in metastatic non-small cell lung cancer (NSCLC) at ESMO 2026.
The trial evaluated Tedopi® in combination with Opdivo® (nivolumab) or docetaxel versus docetaxel alone in 105 HLA-A2 positive patients.
Primary endpoint is 1-year survival rate, with results to be presented October 25, 2026, in Madrid.
Trial conducted across 23 sites in France, Italy, and Spain (NCT04884282).

The big picture

The presentation of Combi-TED Phase 2 results at ESMO 2026 marks a critical milestone for OSE Immunotherapeutics in validating Tedopi® as a potential second-line treatment for metastatic NSCLC. Success here could position the therapy as a key player in the evolving immuno-oncology landscape, where combination therapies are increasingly becoming the standard of care. The trial's international scope and rigorous design underscore its significance in shaping future treatment paradigms for lung cancer.

What we're watching

Clinical Efficacy: Whether Tedopi® in combination with Opdivo® or docetaxel demonstrates superior 1-year survival rates compared to docetaxel alone.
Regulatory Pathway: The pace at which OSE Immunotherapeutics advances Tedopi® into Phase 3 trials based on these results.
Market Positioning: How these results impact OSE Immunotherapeutics' competitive standing in the immuno-oncology space.